American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Apr 2001
Stability of norfloxacin in an extemporaneously prepared oral liquid.
The stability of norfloxacin in an extemporaneously prepared suspension stored at room temperature and under refrigeration was studied over 56 days. A 20-mg/mL suspension was prepared from commercially available 400-mg norfloxacin tablets and equal amounts of Ora-Plus and strawberry syrup to make a final volume of 60 mL. Six identical samples of the suspension were prepared in amber plastic prescription bottles. ⋯ At least 93% of the initial norfloxacin concentration remained throughout the 56-day study period. The color, odor, and pH of all of the samples did not change appreciably. An extemporaneously prepared suspension of norfloxacin 20 mg/mL was stable for at least 56 days when stored at either 23-25 or 3-5 degrees C.
-
Am J Health Syst Pharm · Mar 2001
ReviewTreatment of intermittent claudication with pentoxifylline and cilostazol.
The pathophysiology of intermittent claudication (IC) and the role of pentoxifylline and cilostazol for treating IC are discussed. IC, a result of inadequate blood flow to the musculature, is the primary symptom of occlusive peripheral vascular disease (PVD). Patients with IC often have a decreased quality of life because of mobility limitations. ⋯ Initiation of therapy with either pentoxifylline or cilostazol may be reasonable if risk-factor modifications, lifestyle changes, and antiplatelet therapy are not effective. The mainstays of therapy for IC are risk-factor modification, exercise, and antiplatelet therapy. If these prove inadequate, treatment with pentoxifylline or cilostazol may be reasonable.